Skip to main content

Table 2 Chemotherapy administration and objective response

From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Induction therapy (n = 40) Median cycle (range) 4
(1–4)
Maintenance therapy (n = 35) Median cycle (range) 9
(1–54)
Response (n = 34) CR 0 (0%)
PR 24 (70.6%)
SD 9 (26.5%)
PD 1 (2.9%)